AERI On Watch, LPCN To Be Uplisted, NVGN Back In Focus, PRTA Up After Hours

(RTTNews) - Aerie Pharmaceuticals Inc. (AERI) expects efficacy data from its phase 2b clinical trial for quadruple-action glaucoma product candidate Roclatan to be released in early third-quarter of this year. The company is also expected to begin two phase III registration trials of Rhopressa, also a glaucoma product candidate, in early third-quarter 2014.

AERI closed Tuesday's trading at $21.89, up 5.34%.

Alcobra Ltd. (ADHD) has enrolled the first patient in a phase III clinical trial of its investigational drug MDX in the treatment of adults with Attention Deficit Hyperactivity Disorder. The trial is expected to be completed in the second half of 2014.

ADHD closed Tuesday's trading at $20.79, up 3.43%.

Lipocine Inc. (LPCN.OB) has received approval from NASDAQ Stock Market to uplist its shares on the NASDAQ Capital Market. Accordingly, the company's common stock is expected to begin trading on the NASDAQ Capital Market on or about March 21, 2014, under its current trading symbol "LPCN".

LPCN.OB closed Monday's trading at $8.01, up 4.03%.

Medivation Inc. (MDVN) has submitted a supplemental New Drug Application to FDA seeking approval of XTANDI (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer who have not received chemotherapy.

XTANDI is currently approved for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel chemotherapy.

Medivation and Astellas are jointly responsible for commercialization and development of XTANDI in the U.S. Outside of the U.S., Astellas has responsibility for developing and commercializing XTANDI.

For full year 2013, the drug logged in net sales of $392.4 million in the U.S. and $52.8 million in net sales outside of the U.S.

MDVN closed Tuesday's trading at $70.55, up 2.99%.

Seeking to ensure that there is enough capital, Nanosphere Inc. (NSPH) has entered into a Common Stock Purchase Agreement with its shareholder Aspire Capital Fund, LLC. The agreement allows Nanosphere to sell up to $30 million of shares of its common stock to Aspire Capital under certain conditions from time to time.

NSPH closed Tuesday's trading 5.53% higher at $2.29. In after-hours, the stock gained another 2.18% to $2.34.

Novogen Ltd. (NVGN) and its joint venture company with Yale University, CanTx Inc, announced that their lead candidate drug, Trx-1, designed to fight abdominal cancers, has demonstrated a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells.

CanTx is seeking a novel approach to the treatment of abdominal cancers, by developing a product to be administered intra-peritoneally with the ability to seek out tumor cells and to eliminate the full hierarchy of cells within tumors. The final product is envisaged to be Trx-1 in a 'smart' drug delivery system, said Novogen.

NVGN rose 3.47% on Tuesday to close the day's trading at $4.47.

Prothena Corp. plc (PRTA) is scheduled to present an abstract reviewing interim clinical data from its ongoing phase 1 study of NEOD001 in patients with immunoglobulin light chain (AL) amyloidosis and persistent organ dysfunction at the XIV International Symposium on Amyloidosis (ISA) in Indianapolis, Indiana on April 29, 2014.

NEOD001 was granted orphan drug designation by the FDA in 2012 and by the European Medicines Agency in 2013.

PRTA closed Tuesday's trading at $37.16, down 0.93%. In after-hours, the stock was up 13.62% to $42.22.

Plandaí Biotechnology Inc.'s (PLPL.OB) state-of-the-art production facility for producing its proprietary Phytofare Catechin Complex is scheduled to be commissioned in April of this year.

The Phytofare Catechin Complex is a highly bioavailable green tea extract that will be marketed to nutraceutical companies as an ingredient across a broad spectrum of health and wellness products.

The facility is situated on Senteeko Tea Estate in South Africa.

PLPL.OB rose 7.27% to close Tuesday's trading at $1.18.